Pioglitazone plus metformin for high-risk mouth lesions
Part of Cancer, Mouth & dental clinical trials.
This trial studies whether a two-medicine diabetes drug combination can reduce or control risky early changes in certain mouth and throat lesions. You may be asked for small tissue samples (biopsies) before and after 12 weeks to see how the lesions respond.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older, and you can give written consent.
- A biopsy has already shown abnormal cell growth (hyperplasia or dysplasia) in a high-risk area of the mouth or throat, such as the tongue, floor of mouth, or oropharynx.
- You have measurable oral white or red patches (leukoplakia and/or erythroplakia) that can be measured in two directions, and the main spot must be big enough for a small 4 mm punch biopsy.
- You can take a twice-daily tablet regimen for 12 weeks (swallowing tablets whole).
- You have no major medical “organ function” problems based on recent blood tests done within 14 days of starting the study.
- If you can become pregnant, you agree to reliable birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if metformin — a medication commonly used for diabetes — can prevent oral leukoplakia from turning into cancer when applied as a mouth rinse and taken as a pill. It is for people with non-severe white patches in the mouth.
This trial tests a low-cost approach to find and treat early mouth cancers or precancerous spots using a special light-activated drug (photodynamic therapy). The goal is to destroy the abnormal cells while sparing healthy tissue.
This study tests whether a cream containing coenzyme Q10 and curcumin can help treat a common mouth condition called oral leukoplakia (a white patch that can sometimes turn into cancer). It is for people with a specific type of white patch that is not severe and can be easily reached with a cream.
This study tests whether a light-based treatment (photodynamic therapy) works better than a vitamin D cream (calcipotriol) for treating white patches in the mouth that could become cancer. Both treatments are applied directly to the patch.
This Phase 2 trial studies pembrolizumab (an immune medicine) for leukoplakia and related abnormal mouth patches with moderate/severe pre-cancer changes. It aims to see whether the treatment can shrink or control the lesions when surgery or radiation isn’t an option.
This Phase 2 trial studies whether APG-157 can safely improve abnormal cells in the mouth (dysplasia) or early cancer-like changes (carcinoma in situ). You may be eligible if you have a visible, biopsy-proven lesion and can take oral medication while meeting blood and health requirements.
Hear when a new Oral Leukoplakia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.